Chengdu Olymvax Biopharmaceuticals (SH:688319) Xin Lang Cai Jing·2025-11-24 01:36Core Viewpoint - Oulin Biotech experienced a decline of 5.66% in stock price on November 21, with a trading volume of 95.67 million yuan, indicating potential market volatility and investor sentiment concerns [1]. Financing Summary - On November 21, Oulin Biotech had a financing buy-in amount of 7.32 million yuan and a financing repayment of 11.86 million yuan, resulting in a net financing outflow of 4.54 million yuan [1]. - The total financing and securities balance for Oulin Biotech reached 326 million yuan, accounting for 3.74% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - The company had no short selling activity on November 21, with a short selling balance of 0 yuan, also reflecting a high percentile compared to the past year [1]. Company Performance - As of September 30, Oulin Biotech reported a total of 10,200 shareholders, an increase of 56.42% from the previous period, while the average circulating shares per person decreased by 36.07% to 39,746 shares [2]. - For the period from January to September 2025, Oulin Biotech achieved a revenue of 507 million yuan, representing a year-on-year growth of 31.11%, and a net profit attributable to shareholders of 47.48 million yuan, showing a significant increase of 1079.36% [2]. Dividend and Shareholding Structure - Since its A-share listing, Oulin Biotech has distributed a total of 15.43 million yuan in dividends [3]. - As of September 30, 2025, among the top ten circulating shareholders, the fund "Xingquan Helun Mixed A" held 15.44 million shares, remaining unchanged from the previous period, while "Xingquan Heyi Mixed A" held 8.92 million shares, also unchanged [3]. - A new shareholder, "Xingquan Commercial Model Mixed (LOF) A," entered the top ten with a holding of 4.64 million shares [3].